- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- America's 10 Favorite Fast-Food Burgers
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
Believers in Peregrine's lung cancer drug bavituximab state their case.
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.